FDA approved first oral hormone therapy for teating advanced prostate cancer
On Dec. 18, 2020, tthe U.S. Food and Drug Administration approved Orgovyx (relugolix) for the treatment of adult patients with advanced prostate cancer. The FDA granted approval of Orgovyx to Myovant Sciences.
Tags:
Source: U.S. Food and Drug Administration
Credit:
